secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001680367-22-000014
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs Q1 net loss $24.5M ($0.58/shr); cash $239.2M; SL-172154 dose escalation ongoing
--------------------------------------------------------------------------------

- Net loss $24.5M ($0.58 per share) vs $11.8M ($0.28) YoY; R&D expenses $19.2M, up from $10.3M.
- Cash & short-term investments $239.2M as of Mar 31, 2022, down from $321.2M a year ago; runway into 2H2024.
- Phase 1 dose escalation of SL-172154 in ovarian cancer continues; full monotherapy data expected 1H2023.
- Combination trial of SL-172154 with liposomal doxorubicin in ovarian cancer on track to start 2H2022.
- Phase 1 trial of SL-279252 in solid tumors enrolling; top-line data expected 2H2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036722000014/0001680367-22-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036722000014/sttk-20220512.htm
  HTML page:      https://secwatch.observer/filing/0001680367-22-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer